Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
This is a response to Applicant’s communication filed on August 27, 2024. Application No. 18/815,847, is a Continuation of PCT/JP2023/008501, filed March 7, 2023, and claims foreign priority to Japanese application No. JAPAN 2022-051370, filed March 28, 2022. Claims 1-20 are pending.
Claim Rejections - 35 USC § 102(a)(1)
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
Claims 1-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Khapade et al., US2019/0105268 A1. Khapade discloses a composition for a living body (see Khapade et al., US PGpub ‘268, abstract, for a viscoelastic gel composition comprising liraglutide), comprising:
a neutral acyl lipid containing glyceryl oleate; (see Id., para. [0030], for glyceryl monooleate and glyceryl dioleate)
a phospholipid; (see Id., para. [0031] for phosphatidylcholine)
an alcohol having 4 or less carbon atoms or a polyalkylene oxide; (see Id., para. [0034] for propylene glycol) and
a physiologically active substance, (see Id., Abstract for liraglutide)
wherein a content of a neutral diacyl lipid in the neutral acyl lipid is more than 0% by mass and 50% by mass or less, (see Id., para. [0032]-[0033])
a mass ratio of a content of the neutral acyl lipid to a content of the phospholipid is 54/46 to 1/99, (Id.) and
the composition for a living body is for percutaneous absorption or mucous membrane absorption. (See Id., Abstract.)
Conclusion
No claims are allowed.
Contact Information
Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIMOTHY R ROZOF whose telephone number is (571)270-5992. The examiner can normally be reached Monday - Friday, 9:00 a.m. -5:00 p.m..
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at (571) 272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/TIMOTHY R ROZOF/Primary Examiner, Art Unit 1625
Prosecution Insights